Robert Litman
Rockville, MDNPI 1114041274
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,155 of the $59,894 with a category attached, or 80.4%. Johnson & Johnson accounts for 80.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $51,109 and has fallen 99.7% since, to $176 in 2022.
Across 67 payments — averaging $893.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$48K
- AbbVie$9K
- F. Hoffmann-la Roche AG$3K
- Biohaven Pharmaceuticals, Inc.$134
- Novartis$120
- Vanda Pharmaceuticals Inc.$14
- plus $11 from 1 others
Across 595 payments — averaging $24,725 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3.1M
- Vanda Pharmaceuticals Inc.$2.5M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2.5M
- Sunovion Pharmaceuticals Inc.$2M
- Takeda Pharmaceuticals U.S.A., Inc.$1.5M
- Roche TCRC, Inc.$1.2M
- plus $2M from 13 others
What the payments were for
- Consulting fees$5,1159%
- Speaking & faculty fees$48,15580%
- Travel & lodging$4,9728%
- Food & beverage$1,6523%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 47 | $48,321 |
| AbbVie(2 entities) | 15 | $8,704 |
| F. Hoffmann-la Roche AG | 1 | $2,590 |
| Biohaven Pharmaceuticals, Inc. | 1 | $134 |
| Novartis | 1 | $120 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$47,818
- VRAYLAR$7,880
- NURTEC ODT$134
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluoxetine Hcl | 12 | $224 |
| Trihexyphenidyl Hcl | 13 | $193 |
| Risperidone | 13 | $183 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.